Classement en actions
#14023
Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to... Operating as a clinical-stage biotechnology firm, Q32 Bio Inc. is dedicated to developing biologic therapies aimed at re-establishing healthy immune equilibrium in patients across the United States suffering from autoimmune and inflammatory disorders stemming from dysfunctional immune responses. The company's primary investigational therapy, ADX-097, is a humanized anti-C3d monoclonal antibody fusion protein designed to normalize complement regulation. This candidate has successfully finished its Phase I clinical trial, targeting severe renal and other complement-driven conditions where patient needs are largely unmet, such as lupus nephritis, IgA nephropathy, C3 glomerulopathy, and ANCA-associated vasculitis. Additionally, Q32 Bio is advancing Bempikibart (ADX-914), a fully human monoclonal antibody antagonist against interleukin-7 receptor alpha. Currently in Phase II trials, Bempikibart aims to recalibrate adaptive immune responses by inhibiting signaling pathways involving interleukin-7 and thymic stromal lymphopoietin, offering potential treatment for atopic dermatitis and alopecia areata. Founded in 2017 and headquartered in Waltham, Massachusetts, Q32 Bio Inc. adopted its current name in April 2020, having previously operated as AdMIRx Inc.
Capitalisation boursière
$442.29M
Changement (1 jour)
-1.13%
Changement (1 an)
769.01%
Échange Q32 Bio Inc. (QTTB)
Nombre d'actions en circulation pour Q32 Bio Inc. (QTTB)
Nombre d'actions en circulation au August 2026: 0
Selon les derniers rapports financiers et le cours de l'action de Q32 Bio Inc., le nombre actuel d'actions en circulation est de 0. À la fin de August 2026, l'entreprise avait 0 actions en circulation. Le nombre d'actions en circulation est généralement affecté par les divisions d'actions et les rachats d'actions.
Historique des actions en circulation de Q32 Bio Inc. (QTTB) de 2026 à 2026
Actions en circulation à la fin de chaque année
| Année |
Actions en circulation |
Changez |
|
Pas assez de données pour les dates fournies. |
Actions en circulation pour des entreprises similaires ou concurrentes
| Entreprise |
Actions en circulation |
Différence |
Pays |
|
|
253.90M |
-
|
US
|
|
|
62.19M |
-
|
NL
|
|
|
478.91M |
-
|
AU
|
|
|
396.00M |
-
|
US
|
|
|
- |
-
|
CH
|
